Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANTIVIRALS INC. http://www.antivirals.com -- Ignore unavailable to you. Want to Upgrade?

To: DavidCG who wrote (139)	12/2/1998 12:06:00 PM
From: DELT1970	Respond to of 167

Price lifting announcement today on Phase II Clinical Results Of Lead Cancer Therapeutic, Avicine, In Pancreatic Cancer. This company looks to have the clinical lead and marvelous efficacy, and I hope it will present at the Dec 12 Informed Investors Conference in Seattle focusing on cancer vaccines. The warrant seems a great way to play this stock from here on.

To: DavidCG who wrote (139)	12/19/1998 7:12:00 PM
From: DELT1970	Respond to of 167

How much is a Big Pharma partnersip worth to a cancer vaccine developer? For Cell Genesys, (CEGE), it looks like it might be as much as $80 million from Japan Tobacco. Cell Genesys' GVAX cancer vaccine is pointed toward, prostrate, lung and melanoma, but it is only in Phase I/II trials. When I compare a deal like this to AVII's vaccine entering Phase III, I have to believe AVII will win big dollars as well for a company whose market cap is much smaller than CEGE's. While CEGE has some secondary assets, AVII's drug delivery and antisense programs have got to be worth more than is reflected currently in the stock price. Speaking of antisense, Isis has acquired Gilead's antisense patents and work product. Hmmm